Logo 1 Logo 2

Clinical Trial Details

Trial ID: L4048
Source ID: NCT03269058
Associated Drug: Dapagliflozin
Title: Evaluate the Effects of Dapagliflozin in Patients With Type 2 Diabetes
Acronym: Cinétique DAPA
Status: COMPLETED
Study Results: NO
Results:
Conditions: Type-2 Diabetes|Oral Antidiabetics
Interventions: DRUG: Dapagliflozin|DRUG: Placebos
Outcome Measures: Primary: Change from baseline the rate of production of VLDL Apo B, 15 days before treatment initiation, Day 0, Day 90 and Day 180|Change from baseline the rate of production of IDL Apo B, 15 days before treatment initiation, Day 0, Day 90 and Day 180|Change from baseline the rate of production of LDL Apo B, 15 days before treatment initiation, Day 0, Day 90 and Day 180|Change from baseline the rate of production of HDL Apo A1, 15 days before treatment initiation, Day 0, Day 90 and Day 180|Change from baseline the Fractional Catabolic Rate of VLDL1 Apo B, 15 days before treatment initiation, Day 0, Day 90 and Day 180|Change from baseline the Fractional Catabolic Rate of VLDL2 Apo B, 15 days before treatment initiation, Day 0, Day 90 and Day 180|Change from baseline the Fractional Catabolic Rate of IDL Apo B, 15 days before treatment initiation, Day 0, Day 90 and Day 180|Change from baseline the Fractional Catabolic Rate of LDL Apo B, 15 days before treatment initiation, Day 0, Day 90 and Day 180|Change from baseline the Fractional Catabolic Rate of HDL 'Apo A1, 15 days before treatment initiation, Day 0, Day 90 and Day 180 |
Sponsor/Collaborators: Sponsor: Centre Hospitalier Universitaire Dijon
Gender: ALL
Age: ADULT, OLDER_ADULT
Phases: PHASE4
Enrollment: 28
Study Type: INTERVENTIONAL
Study Designs: Allocation: RANDOMIZED|Intervention Model: PARALLEL|Masking: DOUBLE (PARTICIPANT, INVESTIGATOR)|Primary Purpose: TREATMENT
Start Date: 2017-12-20
Completion Date: 2021-05-06
Results First Posted:
Last Update Posted: 2024-02-23
Locations: CHU Dijon Bourgogne, Dijon, 21079, France|CHU de Nantes, Nantes, 44093, France
URL: https://clinicaltrials.gov/show/NCT03269058